Miglustat: In type 1 gaucher's disease: A slight benefit after imiglucerase therapy

Prescrire International

Volumn 14, Issue 79, 2005, Pages 168-170

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; ALKALINE PHOSPHATASE; CERAMIDE GLUCOSYLTRANSFERASE; GANGLIOSIDE GM1; IMIGLUCERASE; MIGLUSTAT; 1 DEOXYNOJIRIMYCIN; DRUG DERIVATIVE; GLUCOSYLCERAMIDASE; NEW DRUG;

ABDOMINAL PAIN; ARTICLE; BODY WEIGHT DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DEMYELINATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DYSTOCIA; ENZYME ACTIVITY; FLATULENCE; GASTROINTESTINAL TOXICITY; GAUCHER DISEASE; HEADACHE; HEMOGLOBIN DETERMINATION; HOT FLUSH; HUMAN; INFERTILITY; LIVER WEIGHT; MONOTHERAPY; NAUSEA; NERVE FIBER DEGENERATION; PARESTHESIA; PERIPHERAL NEUROPATHY; PRURITUS; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; SPLEEN WEIGHT; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREMOR; WEIGHT REDUCTION; COMPARATIVE STUDY; DRUG COMBINATION;

1-DEOXYNOJIRIMYCIN; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; TREATMENT OUTCOME;

EID: 27144514130     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Stirnemann J et al. "La maladie de Gaucher" Encyclopédie Orphanet, avril 2003. Website http://www.orpha.net/data/patho/FR/fr-gaucher.html consulted on 4 March 2004.
2. Prescrire Rédaction "La maladie de Gaucher, en bref" Rev Prescrire 1996; 16 (158): 35.
3. Prescrire Editorial Staff "Alglucérase" Prescrire Int 1996; 5 (23): 71-72.
4. Prescrire Rédaction "imiglucérase (Cerezymeo) et maladie de Gaucher. Un intérêt confirmé" Rev Prescrire 1999; 19 (200): 746-748.
5. Commission de la transparence "Avis de la commission - Zavesca" 12 November 2003: 8 pages.
6. US Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-348. Approved labelling" 31 July 2003: 19 pages.
7. US Food and Drug Administration - Center for Drug Evaluation and Research "Application number: 21-348. Medical review" 16 June 2003: 256 pages.
8. European Agency for the Evaluation of Medicinal Products" Committee for Proprietary Medicinal Products "European public assessment report - Zavesca. Scientific Discussion" 2003: 29 pages.
9. Actelion "Note d'intérêt thérapeutique Zavesca" 12 March 2004: 6 pages.
10. Cox T et al. "Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis" Lancet 2000; 355: 1481-1485.
11. Heitner R et al. "Low-dose N-butyldeoxynojirimycin (OGT 918) for type 1 Gaudier disease" Blood Cells Mol Dis 2002; 28 (2): 127-133.
12. Us Food and Drug Administration - Center for Drug Evaluation and Research - Division of Neuropharmacological Drug Products (BFD-120)" Consult request on Zavesca (OGT 918) for Gaucher Disease" 10 May 2002: 40 pages.
13. "RD insight - miglustat" Adis 22 January 2004: 11 pages.